CA2950344C - Omega-3 compositions, dosage forms, and methods of use - Google Patents

Omega-3 compositions, dosage forms, and methods of use Download PDF

Info

Publication number
CA2950344C
CA2950344C CA2950344A CA2950344A CA2950344C CA 2950344 C CA2950344 C CA 2950344C CA 2950344 A CA2950344 A CA 2950344A CA 2950344 A CA2950344 A CA 2950344A CA 2950344 C CA2950344 C CA 2950344C
Authority
CA
Canada
Prior art keywords
dosage form
fatty acids
study
dha
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2950344A
Other languages
English (en)
French (fr)
Other versions
CA2950344A1 (en
Inventor
Olav SANDNES
Bruce A. Miller
Jorn DYERBERG
Steen Stender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Ingredients LLC
Original Assignee
Marine Ingredients LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Ingredients LLC filed Critical Marine Ingredients LLC
Publication of CA2950344A1 publication Critical patent/CA2950344A1/en
Application granted granted Critical
Publication of CA2950344C publication Critical patent/CA2950344C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/618Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2950344A 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use Active CA2950344C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US62/009,145 2014-06-06
US201462019289P 2014-06-30 2014-06-30
US62/019,289 2014-06-30
PCT/US2015/034372 WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Publications (2)

Publication Number Publication Date
CA2950344A1 CA2950344A1 (en) 2015-12-10
CA2950344C true CA2950344C (en) 2023-09-19

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2950344A Active CA2950344C (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Country Status (14)

Country Link
US (4) US9675575B2 (https=)
EP (2) EP3906920A1 (https=)
JP (2) JP6755186B2 (https=)
KR (1) KR102400958B1 (https=)
CN (1) CN106687113B (https=)
AU (1) AU2015269307C1 (https=)
BR (1) BR112016028561A8 (https=)
CA (1) CA2950344C (https=)
CL (1) CL2016003131A1 (https=)
MX (1) MX2016015791A (https=)
MY (1) MY186566A (https=)
RU (1) RU2741965C2 (https=)
TW (1) TWI725937B (https=)
WO (1) WO2015188046A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
EP3906920A1 (en) * 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3103355B1 (fr) 2019-11-26 2024-05-31 Polaris Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
CA2236089C (en) * 1995-11-24 2002-03-05 Loders-Croklaan B.V. Composition based on fish oil
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
CA2625338A1 (en) 2005-10-07 2007-06-14 Ocean Nutrition Canada Ltd. Salts of fatty acids and methods of making and using thereof
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
EP1962825B1 (en) 2005-12-21 2014-04-02 Brudy Technology, S.L. Use of dha for treating a pathology associated with cellular oxidative damage
CN101472490A (zh) 2006-06-23 2009-07-01 宝洁公司 浓缩型ω-3脂肪酸以及包含它们的混合物
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
CA2685272A1 (en) * 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
EP2172558B1 (en) * 2007-07-30 2017-07-19 Nippon Suisan Kaisha, Ltd. Method for production of epa-enriched oil and dha-enriched oil
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
RS53694B1 (sr) * 2008-08-07 2015-04-30 Spa Societa' Prodotti Antibiotici S.P.A. Dugoročno lečenje simptomatske srčane insuficijencije
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
WO2010119319A1 (en) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US9675572B2 (en) 2010-04-23 2017-06-13 The United States Of America As Represented By The Secretary Of The Army Intravenous omega-3 fatty acid compositions and method of use
EP2619298B1 (en) * 2010-09-24 2018-09-12 Pronova BioPharma Norge AS Process for concentrating omega-3 fatty acids
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
US20140335061A1 (en) * 2011-12-08 2014-11-13 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
WO2014057362A2 (en) 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
EP3906920A1 (en) 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use

Also Published As

Publication number Publication date
TWI725937B (zh) 2021-05-01
JP2020105224A (ja) 2020-07-09
US11160777B2 (en) 2021-11-02
CN106687113A (zh) 2017-05-17
EP3151826A1 (en) 2017-04-12
BR112016028561A2 (pt) 2017-08-22
CL2016003131A1 (es) 2017-06-09
US20180303784A1 (en) 2018-10-25
CN106687113B (zh) 2021-09-03
US20160243068A1 (en) 2016-08-25
EP3906920A1 (en) 2021-11-10
US9675575B2 (en) 2017-06-13
AU2015269307A1 (en) 2017-01-05
MY186566A (en) 2021-07-27
US10034849B2 (en) 2018-07-31
US20210308086A1 (en) 2021-10-07
RU2016149416A3 (https=) 2018-12-05
MX2016015791A (es) 2017-05-30
KR102400958B1 (ko) 2022-05-20
US20170252313A1 (en) 2017-09-07
JP6755186B2 (ja) 2020-09-16
US10172819B2 (en) 2019-01-08
TW201613571A (en) 2016-04-16
AU2015269307C1 (en) 2019-10-03
JP2017516811A (ja) 2017-06-22
BR112016028561A8 (pt) 2021-06-29
WO2015188046A1 (en) 2015-12-10
AU2015269307B2 (en) 2019-03-14
KR20170018825A (ko) 2017-02-20
RU2741965C2 (ru) 2021-02-01
EP3151826A4 (en) 2018-01-24
CA2950344A1 (en) 2015-12-10
RU2016149416A (ru) 2018-07-10

Similar Documents

Publication Publication Date Title
US11160777B2 (en) Omega-3 compositions, dosage forms, and methods of use
CN103221524B (zh) 用于浓缩omega-3脂肪酸的方法
JP6953504B2 (ja) エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法
CN116173001A (zh) 含有天然专门促消退介质及其前体的具有抗炎活性的油
US20110033595A1 (en) Fatty acid fractionation process, fatty acid products and use thereof
JP2023107827A (ja) 水産物由来遊離1価不飽和脂肪酸又はその低級アルコールエステルの製造方法
JP4904751B2 (ja) 生体内dha合成促進剤
ITUB20153877A1 (it) Metodo di purificazione di gliceridi di acidi grassi, composizioni che ne derivano, e loro uso

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200506

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250527

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250527